Dopamine D4 receptors: Significance for molecular psychiatry at the millennium

Molecular Psychiatry

Volumn 4, Issue 6, 1999, Pages 529-538

  Tarazi, F I ^a,b,c   Baldessarini, R J ^a,b  

^a Mailman Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotics; Attention deficit hyperactivity disorder; D4; Dopamine; mRNA; Parkinson's disease; Psychotic disorders; Receptors; Schizophrenia

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 2 [4 (2,3 DIHYDROBENZO[1,4]DIOXIN 6 YL)PIPERAZIN 1 YLMETHYL]INDAN 2 YL; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 3 [[4 (4 IODOPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 7 (4 FLUOROPHENOXYMETHYL) 2 (5 FLUORO 2 PYRIMIDINYL) 2,3,4,6,7,8,9,9A OCTAHYDROPYRIDO[1,2 A]PYRAZINE; CHLORPROMAZINE; CLOZAPINE; CP 226269; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MELPERONE; N (1 BENZYL 3 PYRROLIDINYL) 5 CHLORO 4 CYCLOPROPYLCARBOXAMIDO 2 METHOXYBENZAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PD 168077; PD 172938; PNU 101958; QUETIAPINE; RBI 257; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SONEPIPRAZOLE; UNCLASSIFIED DRUG; YM 50001; ZIPRASIDONE; DOPAMINE 2 RECEPTOR; DRD4 PROTEIN, HUMAN;

AFFECTIVE NEUROSIS; ATTENTION DEFICIT DISORDER; DNA POLYMORPHISM; DYSTONIA; HUMAN; MOLECULAR CLONING; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPSYCHIATRY; PARKINSON DISEASE; PARKINSONISM; PERSONALITY DISORDER; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; BRAIN LEVEL; CHEMISTRY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHIATRY; PSYCHOSIS;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL PSYCHIATRY; BRAIN CHEMISTRY; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4;

EID: 0032586082     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000674     Document Type: Review

References (120)

1. 1 Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev Psychiatry 1996; 3: 301-325.
2. 2 Neve KA, Neve RL. The Dopamine Receptors. Humana Press: Totowa, New Jersey, 1997.
3. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 1991; 350: 614-619.
4. 4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics 1992; 13: 208-210.
5. 2 receptor. Proc Natl Acad Sci USA 1991; 88: 8111-8115.
6. 4 receptor. Biochemistry 1998; 37: 15726-15736.
7. 4 Dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol Psychiatry 1999; 4: 235-246.
8. 4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system. New Biologist 1992; 4: 137-146.
9. 4 receptor variants in the human population. Nature 1992; 350: 149-152.
10. 4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-773.
11. 4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. J Pharmacol Exp Ther 1994; 46: 364-373.
12. 4 receptor and response tn antipsychotic drugs. Psychopharmacology 1999; 141: 6-10.
13. 13 Adamson MD, Kennedy J, Petronis A, Dean M, Virkkunen M, Linnoila M et al. DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Am J Med Genet 1995; 60: 199-205.
14. 4 receptor gene in the susceptibility to Gilles de La Tourette syndrome in Five Canadian families. Am J Med Genet 1996; 67: 301-303.
15. 4 dopamine receptor genes on chromosome 11. Am J Psychiatry 1994; 151: 1202-1206.
16. 16 Macciardi F, Verga M, Kennedy J, Petronis A, Bersani G, Pancheri P. An association study between schizophrenia and the dopamine receptor genes DRD3 and DRD4 using haplotype relative risk. Hum Heredity 1994; 44: 328-336.
17. 17 Baldessarini RJ. Dopamine receptors and clinical medicine. In: Neve KA, Neve RL (eds). The Dopamine Receptors. Humana Press: Totowa, New Jersey, 1997, pp 457-498.
18. 4 receptors: current basic and clinical status. Int J Neuropsychopharmacol 1999; 2: 41-58.
19. 4 receptor gene: novelty or nonsense? Neuropsychopharmacology 1993; 21: 3-16.
20. 4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121-124.
21. 4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD), a family-based approach. Mol Psychiatry 1998; 3: 38-41.
22. 4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 768-770.
23. 4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord 1996; 40: 7-13.
24. 4 receptor exon 3 repeat polymorphism with Parkinson's disease. Clin Genet 1998; 54: 33-38.
25. 4 dopamine receptor gene and measures of novelty seeking. Nature Genet 1996; 12: 81-84.
26. 4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nature Genet 1996; 12; 78-80.
27. 4 receptor. Neurosci Lett 1995; 199: 69-72.
28. 4 receptor. Mol Brain Res 1995; 29: 157-162.
29. 4 receptor in human cerebral cortex and striatum. J Neurochem 1996; 66: 915-919.
30. 30 Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996; 15: 17-29.
31. 31 Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 1997; 54: 1089-1095.
32. 4 gene expression in human brain. Neurosci Lett 1997; 234: 147-150.
33. 4 dopamine receptor mRNA in postmortem schizophrenic brain. Mol Brain Res 1998; 53: 112-199.
34. 4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophrenia Res 1996; 20: 171-174.
35. 4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996; 219: 163-166.
36. 4 receptors elevated in schizophrenia. Nature 1993; 365: 441-445.
37. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186-2191.
38. 3H] raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 1995; 681: 109-116.
39. 2-Family receptor distribution in human postmortem tissue: an autoradiographic study. NeuroReport 1995; 6: 2505-2512.
40. 4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995; 281: R5-R6.
41. 3H]NGD 94-1 study. Mol Psychiatry 1998; 3: 528-533.
42. 2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. NeuroReport 1996; 7: 1945-1948.
43. 4 sites in schizophrenic brains. Eur J Pharmacol 1996; 314: R3-R5.
44. 4 receptors in rat forebrain. NeuroReport 1997; 8: 3423-3426.
45. 4-like dopamine receptors. Neuropsychophamacology 1997; 17: 186-196.
46. 4-like receptors. Neuroscience: 1998; 83: 169-176.
47. 4-like dopamine receptors: common targets for typical, atypical and experimental antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry 1998; 22: 693-707.
48. 3H]-NGD-94-1. J Pharmacol Exp Ther 1997; 282: 1020-1027.
49. 49 Tarazi FI, Baldessarini RJ. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J Neurosci Res 1999; 55: 401-410.
50. 50 Tarazi FI, Campbell A, Yeghiayan SK, Haldessarini RJ. Localization of glutamate receptor subtypes in candate-putamen and nucleus accumbens septi: comparison of NMDA, AMPA and kainate receptors. Synopse 1998; 30: 227-235.
51. 51 Kelley AE, Domesick VB. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde and retrograde horseradish peroxidase study. Neuroscience 1982; 7: 2321-2335.
52. 4-like receptors. Neuroscience 1998; 87: 1-4.
53. 53 Tarazi FI, Campbell A, Baldessarini RJ. Effects of hippocampal kainic acid lesion on striatolimbic ionotropic glutamate NMDA, AMHA and KA receptors. Neurosci Lett 1998; 250: 13-16.
54. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci 1997; 17: 2519-2530.
55. 4 receptor. J Neurochem 1997; 69: 2169-2178.
56. 4 receptors in GABAergic neurons of the primate brain. Nature 1996; 381: 245-248.
57. 4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 1997; 752: 26-34.
58. bodies. Mol Brain Res 1997; 45: 1-12.
59. 11C]SDZ CLC 756. Synapse 1998; 30: 341-350.
60. 4 receptor. J Neurochem 1997; 68: 804-812.
61. 4 receptor variants. J Neurochem 1995; 65: 1157-1165.
62. 4 dopamine receptor-mediated signaling events determined in transfected chinese hamster ovary cells. J Biol Clhem 1994; 269: 11813-11819.
63. 4 receptor inhibits an L-type calcium current in cerebellar granule cells. Neuroscience 1995; 68: 107-116.
64. 4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals. J Pharmacol Exp Ther 1998; 284: 542-548.
65. 4 receptor-mediated inhibition of cyclic: adenosine 3′, 5′-monophosphate production does not affect prolactin regulation. Endocrinology 1997; 138: 1871-1878.
66. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 1997; 90: 991-1001.
67. 4 receptors in rat brain by NIPS. Neorosci Lett 1999; (in press).
68. 4 dopamine receptor affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995; 120: 365-368.
69. 4 receptors. Neuropsychopharmacology 1997; 16: 93-110.
70. 70 Baldessarini RJ, Frankenburg FR. Clozapine - a novel antipsychotic agent. N Engl J Med 1991; 324: 746-754.
71. 71 Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995; 13: 177-213.
72. 72 Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman's The Pharmacologic Basis of Therapeutics. McGraw-Hill: New York, 1996, pp 399-459.
73. 73 Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Vangompol P, Lesage AS et al. Risperidone compared with new and reference antipsychotic drugs - in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
74. 4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol 1998; 351: 273-286.
75. 75 Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991; 43: 587-604.
76. 4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role; sulpiride not stereoselective. Eur J Pharmacol 1993; 233: 173-174.
77. 77 Baldessarini RJ, Kula NS, Zong R, Neumeyer JL. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur J Pharmacol 1994; 254: 199-203.
78. 78 Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL. Behavioral effects of apomorphine isomers in the rat: selective locomotor-inhibitory effects of S(+)N-π-propylnorapomorphine. Psychopharmacology 1986; 88: 158-164.
79. 79 Campbell A, Yeghiayan S, Baldessarini RJ, Neumeyer JL. Selective antidopaminergic effects of S(+)-N-ponpylnoraporphines in limbic vs extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology 1991; 103: 323-329.
80. 80 Nemeroff CB. Kilts CD, Levant B, Bissette G, Camphell A, Baldessarini RJ. Effects of aporphine isomers and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacool-ogy 1991; 4: 27-33.
81. 4 receptors by 2-fold in rats. Eur J Pharmacol 1995; 289: 67-72.
82. 82 Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation following 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997; 280: 561-509.
83. 83 Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience 1997; 78: 985-996.
84. 4 receptors in rat frontal cortex. J Neural Transm 1995; 101: 231-235.
85. 2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994; 91: 4353-4356.
86. 86 Lidow MS, William GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998; 19: 136-140.
87. 87 Kebabian JW, Tarazi FI, Kula NS. Baldessarini RJ. Compounds selective for dopamine receptor subtypes. Drug Discovery Today 1997; 2: 333-340.
88. 4 receptor antagonists. Expert Opin Ther Patents 1998; 8: 383-393.
89. 4 receptor. J Med Chem 1996; 39: 1941-1942.
90. 4 receptor. Mol Pharmacol 1996; 50: 1658-1664.
91. 4 receptor antagonist. NeuroReport 1996; 7: 2543-2546.
92. 4 receptor antagonists: synthesis and structure-activity relationships of (S)(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)-amino]-2-methoxybenzamide (YM-43611) and related compounds. J Med Chem 1996; 39: 2764-2772.
93. 4 receptor selective antagonist. J Pharmacol Exp Ther 1996; 279: 1392-1403.
94. 4-selective dopamine receptor ligand. Eur J Pharmacol 1997; 331: 333-336.
95. 4-selective radioligands. Eur J Pharmacol 1999; 367: 139-142.
96. ZA receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutlyl]pyrrolidin-3-yl]thiazole (NRA-0045). J Pharmacol Exp Ther 1997; 282: 56-63.
97. 4 and 5-hydroxytryptaminte-2A receptor antagonist, in rats. Br J Pharmacol 1997; 121: 515-525.
98. 4 receptor. J Pharmacol Exp Ther 1997; 282: 1011-1019.
99. 4 receptor antagonists: 1-aryloxy-3-(4-aryloxypiperidinyl)-2-propanols. Bioorg Med Chem Lett 1997; 7: 1377-1380.
100. 4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 1998; 287: 176-186.
101. 4 receptor antagonist. Bioorganic Med Chem Lett 1998; 8: 725-730.
102. 4 receptor. Eur J Pharmacol 1996; 314: 229-233.
103. 4 agonists. J Med Chem 1997; 40: 1771-1772.
104. 4 receptor agonist (Abstract 271.11). Soc Neurosci Abst 1997; 23: 685.
105. 4.4 receptor. Br J Pharmacol 1998; 124: 889-896.
106. 4.4 receptor. Eur J Pharmacol 1999; 372: R9-R10.
107. 1 receptor-like sites in human cerebellum and neuroblastoma cells. Eur J Pharmacol 1999; 370: 205-209.
108. 4 receptors expressed in CHO cells. Life Sci 1997; 60: 1-100.
109. 109 Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994; 51: 139-154.
110. 110 Jackson DM, Westlind-Danielsson. A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther 1994; 64: 291-369.
111. 111 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
112. 4 recep tor antagonist does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 1997; 283: 1256-1263.
113. 4 receptor antagonist L-745,870: effects in rats discriminating cocaine from saline. Eur J Pharmacol 1998; 345: 129-132.
114. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 1999; 142: 78-84.
115. 4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations: treatment with antipsychotic drugs. J Pharmacol Exp Ther 1998; 286: 497-508.
116. 4 dopamine antagonist with an in vitro and in vivo profile suggestive of an atypical antipsychotic (abstract 697.1). Soc Neurosci Abst 1996: 22: 1771.
117. 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194-200.
118. 4 dopamine receptor antagonist (L-745, 870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997; 54: 567-572.
119. 2A antagonist fanaserin in the treatment of schizophrenia. Am J Psychiatry 1999; 156: 419-425.
120. 4.4 receptors: actions of antiparkinsonina and antipsychotic agents. J Pharmacol Exp Ther 1997; 282: 181-191.